{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T12:19:38Z","timestamp":1791289178482,"version":"4.3.0"},"reference-count":40,"publisher":"BMJ","issue":"3","license":[{"start":{"date-parts":[[2021,3,3]],"date-time":"2021-03-03T00:00:00Z","timestamp":1614729600000},"content-version":"unspecified","delay-in-days":2,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"FIMA"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2021,1,12]]},"published-print":{"date-parts":[[2021,3]]},"abstract":"<jats:sec>\n                  <jats:title>Introduction<\/jats:title>\n                  <jats:p>The use of immune-checkpoint inhibitors has drastically improved the management of patients with non-small cell lung cancer (NSCLC), but innate and acquired resistances are hurdles needed to be solved. Immunomodulatory drugs that can reinvigorate the immune cytotoxic activity, in combination with antiprogrammed cell death 1 (PD-1) antibody, are a great promise to overcome resistance. We evaluated the impact of the SRC family kinases (SFKs) on NSCLC prognosis, and the immunomodulatory effect of the SFK inhibitor dasatinib, in combination with anti-PD-1, in clinically relevant mouse models of NSCLC.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>A cohort of patients from University Clinic of Navarra (n=116) was used to study immune infiltrates by multiplex immunofluorescence (mIF) and YES1 protein expression in tumor samples. Publicly available resources (TCGA, Km Plotter, and CIBERSORT) were used to study patient\u2019s survival based on expression of SFKs and tumor infiltrates. Syngeneic NSCLC mouse models 393P and UNSCC680AJ were used for in vivo drug testing.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Among the SFK members, YES1 expression showed the highest association with poor prognosis. Patients with high YES1 tumor levels also showed high infiltration of CD4+\/FOXP3+ cells (regulatory T cells (Tregs)), suggesting an immunosuppressive phenotype. After testing for YES1 expression in a panel of murine cell lines, 393P and UNSCC680AJ were selected for in vivo studies. In the 393P model, dasatinib+anti-PD-1 treatment resulted in synergistic activity, with 87% tumor regressions and development of immunological memory that impeded tumor growth when mice were rechallenged. In vivo depletion experiments further showed that CD8+ and\u2009CD4+ cells are necessary for the therapeutic effect of the combination. The antitumor activity was accompanied by a very significant decrease in the number of Tregs, which was validated by mIF in tumor sections. In the UNSCC680AJ model, the antitumor effects of dasatinib+anti-PD-1 were milder but similar to the 393P model. In in vitro assays, we demonstrated that dasatinib blocks proliferation and transforming growth factor beta-driven conversion of effector CD4+ cells into Tregs through targeting of phospholymphocyte-specific protein tyrosine kinase and downstream effectors pSTAT5 and pSMAD3.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>YES1 protein expression is associated with increased numbers of Tregs in patients with NSCLC. Dasatinib synergizes with anti-PD-1 to impair tumor growth in NSCLC experimental models. This study provides the preclinical rationale for the combined use of dasatinib and PD-1\/programmed death-ligand 1 blockade to improve outcomes of patients with NSCLC.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/jitc-2020-001496","type":"journal-article","created":{"date-parts":[[2021,3,3]],"date-time":"2021-03-03T11:43:49Z","timestamp":1614771829000},"page":"e001496","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":73,"title":["SRC family kinase (SFK) inhibitor dasatinib improves the antitumor activity of anti-PD-1 in NSCLC models by inhibiting Treg cell conversion and proliferation"],"prefix":"10.1136","volume":"9","clinical-trial-number":[{"clinical-trial-number":"nct02750514","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Esther","family":"Redin","sequence":"first","affiliation":[{"name":"IDISNA and Program in Solid Tumors, Center for Applied Medical Research (CIMA), University of Navarra, Pamplona, Spain"},{"name":"CIBERONC, ISCIII, Madrid, Spain"},{"name":"Department of Pathology, Anatomy and Physiology, School of Medicine, University of Navarra, Pamplona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irati","family":"Garmendia","sequence":"additional","affiliation":[{"name":"IDISNA and Program in Solid Tumors, Center for Applied Medical Research (CIMA), University of Navarra, Pamplona, Spain"},{"name":"Department of Pathology, Anatomy and Physiology, School of Medicine, University of Navarra, Pamplona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Lozano","sequence":"additional","affiliation":[{"name":"Immunology and Immunotherapy Program, Center for Applied Medical Research (CIMA), University of Navarra, Pamplona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Serrano","sequence":"additional","affiliation":[{"name":"IDISNA and Program in Solid Tumors, Center for Applied Medical Research (CIMA), University of Navarra, Pamplona, Spain"},{"name":"Department of Pathology, Anatomy and Physiology, School of Medicine, University of Navarra, Pamplona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaiza","family":"Senent","sequence":"additional","affiliation":[{"name":"IDISNA and Program in Solid Tumors, Center for Applied Medical Research (CIMA), University of Navarra, Pamplona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0120-0779","authenticated-orcid":false,"given":"Miriam","family":"Redrado","sequence":"additional","affiliation":[{"name":"IDISNA and Program in Solid Tumors, Center for Applied Medical Research (CIMA), University of Navarra, Pamplona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Villalba","sequence":"additional","affiliation":[{"name":"Department of Pathology, University Clinic of Navarra, Pamplona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos E","family":"De Andrea","sequence":"additional","affiliation":[{"name":"Department of Pathology, Anatomy and Physiology, School of Medicine, University of Navarra, Pamplona, Spain"},{"name":"Department of Pathology, University Clinic of Navarra, Pamplona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5406-0768","authenticated-orcid":false,"given":"Francisco","family":"Exposito","sequence":"additional","affiliation":[{"name":"IDISNA and Program in Solid Tumors, Center for Applied Medical Research (CIMA), University of Navarra, Pamplona, Spain"},{"name":"CIBERONC, ISCIII, Madrid, Spain"},{"name":"Department of Pathology, Anatomy and Physiology, School of Medicine, University of Navarra, Pamplona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Ajona","sequence":"additional","affiliation":[{"name":"IDISNA and Program in Solid Tumors, Center for Applied Medical Research (CIMA), University of Navarra, Pamplona, Spain"},{"name":"CIBERONC, ISCIII, Madrid, Spain"},{"name":"Department of Biochemistry and Genetics, School of Sciences, University of Navarra, Pamplona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Ortiz-Espinosa","sequence":"additional","affiliation":[{"name":"IDISNA and Program in Solid Tumors, Center for Applied Medical Research (CIMA), University of Navarra, Pamplona, Spain"},{"name":"Department of Biochemistry and Genetics, School of Sciences, University of Navarra, Pamplona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Remirez","sequence":"additional","affiliation":[{"name":"IDISNA and Program in Solid Tumors, Center for Applied Medical Research (CIMA), University of Navarra, Pamplona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Bertolo","sequence":"additional","affiliation":[{"name":"IDISNA and Program in Solid Tumors, Center for Applied Medical Research (CIMA), University of Navarra, Pamplona, Spain"},{"name":"CIBERONC, ISCIII, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Sainz","sequence":"additional","affiliation":[{"name":"IDISNA and Program in Solid Tumors, Center for Applied Medical Research (CIMA), University of Navarra, Pamplona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juana","family":"Garcia-Pedrero","sequence":"additional","affiliation":[{"name":"CIBERONC, ISCIII, Madrid, Spain"},{"name":"Department of Otolaryngology, Hospital Universitario Central de Asturias and Instituto de Investigaci\u00f3n Sanitaria del Principado de Asturias (ISPA), Instituto Universitario de Oncolog\u00eda del Principado de Asturias, University of Oviedo, Oviedo, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruben","family":"Pio","sequence":"additional","affiliation":[{"name":"IDISNA and Program in Solid Tumors, Center for Applied Medical Research (CIMA), University of Navarra, Pamplona, Spain"},{"name":"CIBERONC, ISCIII, Madrid, Spain"},{"name":"Department of Biochemistry and Genetics, School of Sciences, University of Navarra, Pamplona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1641-3881","authenticated-orcid":false,"given":"Juan","family":"Lasarte","sequence":"additional","affiliation":[{"name":"Immunology and Immunotherapy Program, Center for Applied Medical Research (CIMA), University of Navarra, Pamplona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jackeline","family":"Agorreta","sequence":"additional","affiliation":[{"name":"IDISNA and Program in Solid Tumors, Center for Applied Medical Research (CIMA), University of Navarra, Pamplona, Spain"},{"name":"CIBERONC, ISCIII, Madrid, Spain"},{"name":"Department of Pathology, Anatomy and Physiology, School of Medicine, University of Navarra, Pamplona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis M","family":"Montuenga","sequence":"additional","affiliation":[{"name":"IDISNA and Program in Solid Tumors, Center for Applied Medical Research (CIMA), University of Navarra, Pamplona, Spain"},{"name":"CIBERONC, ISCIII, Madrid, Spain"},{"name":"Department of Pathology, Anatomy and Physiology, School of Medicine, University of Navarra, Pamplona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4074-4242","authenticated-orcid":false,"given":"Alfonso","family":"Calvo","sequence":"additional","affiliation":[{"name":"IDISNA and Program in Solid Tumors, Center for Applied Medical Research (CIMA), University of Navarra, Pamplona, Spain"},{"name":"CIBERONC, ISCIII, Madrid, Spain"},{"name":"Department of Pathology, Anatomy and Physiology, School of Medicine, University of Navarra, Pamplona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2021,3,3]]},"reference":[{"key":"2025100304035805000_9.3.e001496.1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-1538"},{"key":"2025100304035805000_9.3.e001496.2","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.ejca.2016.12.041","article-title":"Immunotherapy revolutionises non-small-cell lung cancer therapy: results, perspectives and new challenges","volume":"78","author":"Giroux Leprieur","year":"2017","journal-title":"Eur J Cancer"},{"key":"2025100304035805000_9.3.e001496.3","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.jtho.2018.04.008","article-title":"Perspectives on Acquired Resistance to PD-1 Axis Inhibitors in Patients with Non-Small Cell Lung Cancer","volume":"13","author":"Tseng","year":"2018","journal-title":"J Thorac Oncol"},{"key":"2025100304035805000_9.3.e001496.4","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.jtho.2018.03.008","article-title":"Clinical features and management of acquired resistance to PD-1 axis inhibitors in 26 patients with advanced non-small cell lung cancer","volume":"13","author":"Gettinger","year":"2018","journal-title":"J Thorac Oncol"},{"key":"2025100304035805000_9.3.e001496.5","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1002\/cncr.32468","article-title":"Biomarkers for immune checkpoint inhibition in non-small cell lung cancer (NSCLC)","volume":"126","author":"Bodor","year":"2020","journal-title":"Cancer"},{"key":"2025100304035805000_9.3.e001496.6","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2017.01.017"},{"key":"2025100304035805000_9.3.e001496.7","doi-asserted-by":"publisher","DOI":"10.1038\/nrd4591"},{"key":"2025100304035805000_9.3.e001496.8","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-10-2616"},{"key":"2025100304035805000_9.3.e001496.9","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2009.46"},{"key":"2025100304035805000_9.3.e001496.10","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2010.01501.x"},{"key":"2025100304035805000_9.3.e001496.11","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.30.5474"},{"key":"2025100304035805000_9.3.e001496.12","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-16-0061-T"},{"key":"2025100304035805000_9.3.e001496.13","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aav2437"},{"key":"2025100304035805000_9.3.e001496.14","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201807-1292OC"},{"key":"2025100304035805000_9.3.e001496.15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2015.09.009"},{"key":"2025100304035805000_9.3.e001496.16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1001216"},{"key":"2025100304035805000_9.3.e001496.17","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.3390\/jcm8122134","article-title":"Tmprss4: a novel tumor prognostic indicator for the stratification of stage Ia tumors and a liquid biopsy biomarker for NSCLC patients","volume":"8","author":"Villalba","year":"2019","journal-title":"J Clin Med"},{"key":"2025100304035805000_9.3.e001496.18","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1210493"},{"key":"2025100304035805000_9.3.e001496.19","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-16-1184"},{"key":"2025100304035805000_9.3.e001496.20","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.jtho.2016.01.013","article-title":"Successful immunotherapy against a transplantable mouse squamous lung carcinoma with anti-PD-1 and Anti-CD137 monoclonal antibodies","volume":"11","author":"Azpilikueta","year":"2016","journal-title":"J Thorac Oncol"},{"key":"2025100304035805000_9.3.e001496.21","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0079798","article-title":"Differential effects of drugs targeting cancer stem cell (CSC) and non-CSC populations on lung primary tumors and metastasis","volume":"8","author":"Larzabal","year":"2013","journal-title":"PLoS One"},{"key":"2025100304035805000_9.3.e001496.22","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1002\/ijc.28574","article-title":"New syngeneic inflammatory-related lung cancer metastatic model harboring double KRAS\/WWOX alterations","volume":"135","author":"Bleau","year":"2014","journal-title":"Int J Cancer"},{"key":"2025100304035805000_9.3.e001496.23","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.canlet.2019.03.013","article-title":"Targeting of TMPRSS4 sensitizes lung cancer cells to chemotherapy by impairing the proliferation machinery","volume":"453","author":"Exposito","year":"2019","journal-title":"Cancer Lett"},{"key":"2025100304035805000_9.3.e001496.24","doi-asserted-by":"publisher","DOI":"10.1038\/ni1445"},{"key":"2025100304035805000_9.3.e001496.25","doi-asserted-by":"publisher","DOI":"10.1038\/nmeth.3337"},{"key":"2025100304035805000_9.3.e001496.26","doi-asserted-by":"crossref","first-page":"773","DOI":"10.2147\/DDDT.S80207","article-title":"The role of dasatinib in the management of chronic myeloid leukemia","volume":"9","author":"Chen","year":"2015","journal-title":"Drug Des Devel Ther"},{"key":"2025100304035805000_9.3.e001496.27","doi-asserted-by":"crossref","unstructured":"Tanaka A , Nishikawa H , Noguchi S , et al . Tyrosine kinase inhibitor imatinib augments tumor immunity by depleting effector regulatory T cells. J Exp Med 2020;217.doi:10.1084\/jem.20191009","DOI":"10.1084\/jem.20191009"},{"key":"2025100304035805000_9.3.e001496.28","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20030152"},{"key":"2025100304035805000_9.3.e001496.29","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-18-0099"},{"key":"2025100304035805000_9.3.e001496.30","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-15-1439"},{"key":"2025100304035805000_9.3.e001496.31","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-019-0179-8"},{"key":"2025100304035805000_9.3.e001496.32","doi-asserted-by":"publisher","DOI":"10.1038\/nature14404"},{"key":"2025100304035805000_9.3.e001496.33","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2010.10.002"},{"key":"2025100304035805000_9.3.e001496.34","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2017.10.022"},{"key":"2025100304035805000_9.3.e001496.35","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-06-3633"},{"key":"2025100304035805000_9.3.e001496.36","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.cytogfr.2016.02.003","article-title":"The light and the dark sides of interleukin-10 in immune-mediated diseases and cancer","volume":"30","author":"Geginat","year":"2016","journal-title":"Cytokine Growth Factor Rev"},{"key":"2025100304035805000_9.3.e001496.37","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2011.03.018"},{"key":"2025100304035805000_9.3.e001496.38","doi-asserted-by":"publisher","DOI":"10.1378\/chest.117.2.365"},{"key":"2025100304035805000_9.3.e001496.39","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00129306"},{"key":"2025100304035805000_9.3.e001496.40","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1007\/s00262-016-1906-6","article-title":"Anti-PD-1 inhibits Foxp3+ Treg cell conversion and unleashes intratumoural effector T cells thereby enhancing the efficacy of a cancer vaccine in a mouse model","volume":"65","author":"Dyck","year":"2016","journal-title":"Cancer Immunol Immunother"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2020-001496","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T11:04:27Z","timestamp":1759489467000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2020-001496"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":40,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2021,3,3]]},"published-print":{"date-parts":[[2021,3]]}},"alternative-id":["10.1136\/jitc-2020-001496"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2020-001496","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3]]}}}